Goldman Sachs
FRTX

Goldman Sachs’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Goldman Sachs’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-44
Closed -$430K – 6738
2013
Q2 		$430K Buy
+44
New +$487K ﹤0.01% 5057

Other funds holding FRTX

PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSWM
Smith Salley Wealth Management Greensboro, North Carolina $2.3B AUM 38.65% 1-Year Est. Return

Goldman Sachs's FRTX Position: Q3 2020 in Review

Goldman Sachs sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2020, closing a stake of 1,651 shares — an estimated $74K sold.

Goldman Sachs first reported a position in FRTX in Q2 2013 and held it in 18 quarters. The position peaked at $400K in Q3 2014. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2020.

  • Goldman Sachs reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,651 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $74K.
  • Goldman Sachs first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $400K in Q3 2014.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.